Orion Portfolio Solutions LLC Has $1.65 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Orion Portfolio Solutions LLC reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 12.0% in the 4th quarter, Holdings Channel reports. The firm owned 19,739 shares of the biopharmaceutical company’s stock after selling 2,695 shares during the period. Orion Portfolio Solutions LLC’s holdings in Intra-Cellular Therapies were worth $1,649,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in ITCI. Norges Bank acquired a new position in Intra-Cellular Therapies during the 4th quarter worth $268,347,000. EFG Asset Management North America Corp. lifted its position in shares of Intra-Cellular Therapies by 99.8% during the 4th quarter. EFG Asset Management North America Corp. now owns 74,190 shares of the biopharmaceutical company’s stock worth $6,200,000 after purchasing an additional 37,061 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after purchasing an additional 93,107 shares during the period. LPL Financial LLC boosted its stake in Intra-Cellular Therapies by 38.7% during the 4th quarter. LPL Financial LLC now owns 28,258 shares of the biopharmaceutical company’s stock valued at $2,360,000 after purchasing an additional 7,878 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in Intra-Cellular Therapies in the 4th quarter worth approximately $1,392,000. Institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ITCI shares. Piper Sandler reissued a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday, March 28th. They set a “hold” rating for the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday. Finally, Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Hold” and an average price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $131.87 on Friday. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98. The stock’s 50-day moving average price is $129.53 and its two-hundred day moving average price is $101.03.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. As a group, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.